Arecor Therapeutics 

Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products. In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.